ADCT
ADC Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
ADCT Profile
Adc Therapeutics Sa
A Swiss-based biotech company that develops antibody-drug conjugates for cancer treatment
Pharmaceutical
06/06/2011
05/15/2020
New York Stock Exchange
263
12-31
Common stock
Biopole, Route de la Corniche 3B, 1066 Epalinges, Switzerland
--
ADC Therapeutics SA was incorporated under the laws of Switzerland on June 6, 2011. The company is a fully integrated commercial-stage biotechnology company that helps improve the lives of cancer patients with next-generation targeted antibody-drug conjugates. The company's flagship product, ZYNLONTA (loncastuximab tesirine or Lonca), received accelerated approval from the FDA on April 23, 2021 and was launched in the United States shortly thereafter for the treatment of adult patients with relapsed or refractory large B-cell lymphoma treated with two or more systems, Including diffuse large B-cell lymphoma not otherwise described, DLBCL caused by low-grade lymphoma, and high-grade B-cell lymphoma. The company's goal is to establish ZYNLONTA as the third-line + DLBCL standard of care, while exploring the application of ZYNLONTA in early treatment and combination to expand market opportunities.